Philips Healthcare has received clearance from the U.S. Food and Drug Administration (FDA) for the latest release of its Capsule Surveillance software for monitoring patients.
Capsule Surveillance is designed to identify emerging signs of patient deterioration and offer a better look at patient data than existing methods. It's designed to facilitate the oversight of patients at mobile locations, electronic intensive care units (eICUs), and over virtual connections with patients.
The latest release of the software covers additional use cases for Capsule Surveillance and new ways to access patient information. The software can now be used with existing mobile clinical communication and collaboration tools at hospitals, as well as eICUs and virtual care population health management systems. This gives clinicians better visibility into live streaming data, waveforms, device alarms, and contextual alerts, according to the company.
The new release of Capsule Surveillance will begin shipping in the second quarter of 2022 to limited sites in the U.S.
